Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

por Kaneko, Yutaro, Hatano, Ryo, Hirota, Naoto, Isambert, Nicolas, Trillet-Lenoir, Véronique, You, Benoit, Alexandre, Jérôme, Zalcman, Gérard, Valleix, Fanny, Podoll, Thomas, Umezawa, Yoshimi, Takao, Seiichi, Iwata, Satoshi, Hosono, Osamu, Taguchi, Tetsuo, Yamada, Taketo, Dang, Nam H., Ohnuma, Kei, Angevin, Eric, Morimoto, Chikao
Publicado 2021